Subgroup analyses on the prevalence of pruritus in patients with diabetes mellitus, anxiety, or depression and the potential impact on the tolerability of FXR agonists have not been performed in the clinical NASH trials published so far [7,24,25,26]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.